Skip to main content
Caplight Logo









CoImmune, Inc.

CoImmune, Inc.

Private
Durham, North CarolinaHealthcare & Life Scienceshttp://benecyte.com

Last Round

Series A

Nov 10, 2020

Total Funding Raised

$56.1M

Company Overview

CoImmune, Inc. is a biotechnology company that specializes in the development of immuno-oncology therapies based on its two proprietary platform technologies, an autologous RNA-loaded dendritic cell technology and an allogeneic CAR-CIK technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cellular immunotherapyimmuno-oncologycell therapy for canceroff-the-shelf cell therapyallogeneic cell therapyCAR-CIK therapyautologous dendritic cell therapydendritic cell therapycytokine-induced killer cellsCIK cellsCAR-T alternativerenal cell carcinomaacute lymphoblastic leukemiacord blood cell therapyclinical-stage biotechSEAKER platformOrexiCAR technology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CoImmune, Inc. Comparables

Compare CoImmune, Inc. with similar companies based on industry and business-model similarity.

CoImmune, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Diakonos Oncology
82%
CellxLife
80%
AiVita Biomedical
74%

CoImmune, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 10, 2020
Corporate FundingFeb 13, 2019

CoImmune, Inc. Investors

Notable investors and investment history

CoImmune, Inc. investors
InvestorRounds
DSC InvestmentSeries A
Korea Investment PartnersSeries A
SCM LifescienceCorporate Funding, Series A
Brain Asset Management Co.,Ltd.Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2020

    $45M round with SCM Lifescience and Genexine Inc.

  • Feb 13, 2019

    $11.1M raised from SCM Lifescience and Genexine Inc.

CoImmune, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CoImmune, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CoImmune, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Year Founded2019
Last FundingNov 10, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?